^
Association details:
| Biomarker: | ER mutation |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | exemestane (Aromatase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Published date:
10/08/2020
Excerpt:
Patients with ESR1 mutation detected had 1-year OS of 62% (95% CI, 45%–75%) on exemestane and 80% (95% CI, 68%–87%) on fulvestrant (P = 0.04; restricted mean survival analysis)....Detection of ESR1 mutations in baseline ctDNA is associated with inferior PFS and OS in patients treated with exemestane versus fulvestrant.
DOI:
10.1158/1078-0432
